Welcome to our dedicated page for Adaptin Bio SEC filings (Ticker: APTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Adaptin Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Adaptin Bio's regulatory disclosures and financial reporting.
Adaptin Bio, Inc., an emerging growth biopharmaceutical company focused on delivering therapeutics across the blood-brain barrier for brain cancers and other CNS and systemic diseases, has filed a post-effective amendment to its Form S-1 for a continuous Rule 415 offering. The amendment updates the prospectus for the resale of up to 1,901,482 outstanding shares of common stock by selling stockholders and the company’s potential issuance of up to 2,233,083 additional shares upon exercise of outstanding A, B and Pre-Merger warrants. Adaptin’s common stock trades on the OTCQB under “APTN,” with a last quoted price of $6.25 per share on July 14, 2026, and there were 9,079,416 shares outstanding as of July 16, 2026.
The company will not receive proceeds from share resales but would receive cash only upon warrant exercises. The registered securities represent a potential sale of 4,134,565 shares, about 31.8% of fully diluted shares, which the company states could pressure liquidity and trading prices. Officers and directors are subject to a two-year lock-up from first OTC or exchange trading. Adaptin remains pre-revenue, with its lead candidate APTN-101 entering first-in-human brain cancer studies, and its auditor has expressed substantial doubt about its ability to continue as a going concern. The company discloses that significant additional capital will be needed by or before 2026 to fund clinical development and that failure to raise funds could force it to scale back programs, pursue dilutive financings or consider liquidation.
Adaptin Bio, Inc. files a prospectus supplement to register the resale of 1,901,482 shares of common stock and 2,233,083 shares underlying warrants held by selling stockholders, as part of its Form S-1 shelf.
The supplement attaches Amendment No. 1 to the Company’s Form 10-K for the fiscal year ended December 31, 2025, which updates Item 15(b) and Exhibit 23.1 to add an updated auditor consent. The auditor's consent includes an explanatory paragraph stating substantial doubt about the Company’s ability to continue as a going concern.
Shares outstanding were 8,903,229 as of June 11, 2026, and the last quoted OTCQB price was $6.18 per share on June 9, 2026. The registration covers resale by selling holders; proceeds treatment is identified as resale by holders.
Adaptin Bio, Inc. filed an Amendment No. 1 to its annual report for the year ended December 31, 2025. The update is narrow and revises Item 15(b) and Exhibit 23.1 to provide an updated consent from WithumSmith+Brown, PC, its independent registered public accounting firm, to reference a company registration statement that was previously omitted.
The company states that no other financial or non-financial information from the original annual report has been changed and that the amendment does not reflect events occurring after the original filing. As of June 11, 2026, Adaptin Bio had 8,903,229 shares of common stock outstanding, and its non‑affiliate equity market value was approximately $9.3 million as of June 30, 2025.
Adaptin Bio, Inc. files a prospectus supplement updating its S-1 to register resale of 1,901,482 shares of common stock and notes 2,233,083 shares underlying warrants held by selling stockholders. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026, its Form 10-K for fiscal 2025 and an 8-K.
The Company reported $301,309 in cash as of March 31, 2026, a net loss of $1,146,096 for Q1 2026 and an accumulated deficit of $10,437,897. Shares outstanding were stated as 8,851,229 as of May 14, 2026. The supplement updates offering and disclosure materials and should be read with the underlying Prospectus.
Adaptin Bio, Inc. reported a Q1 2026 net loss of $1,146,096, wider than the prior-year loss of $603,084, as it increased investment in R&D and public-company overhead.
The company ended March 31, 2026 with cash and equivalents of $301,309 and an accumulated deficit of $10,437,897. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern and expects to rely on additional equity or debt financings. During the quarter, Adaptin raised gross proceeds of $652,000 through its Follow-on Offering, issued 130,400 new shares, and continued advancing its APTN-101 brain cancer program while operating with a working capital deficit.
Adaptin Bio, Inc. reported that its common shares have been approved for quotation on the OTCQB Venture Market under the ticker symbol APTN. The company expects trading to begin in approximately 6–8 weeks and plans to share any material updates as they occur.
Adaptin is a biotechnology company developing precision cancer therapeutics focused on hard-to-reach tissues, including the brain. Its lead candidate, APTN-101, a brain bispecific T cell engager built on the BRiTE delivery platform, is FDA-cleared for a Phase 1 clinical trial in glioblastoma and has shown anti-tumor activity and a favorable safety profile in multiple preclinical models.
Adaptin Bio, Inc. is an early-stage biopharmaceutical company developing its BRiTE platform to deliver therapeutics across the blood-brain barrier, with lead candidate APTN-101 targeting EGFRvIII-positive glioblastoma and other cancers. The company completed a merger with Unite Acquisition 1 Corp. in February 2025, becoming a public entity.
For the year ended December 31, 2025, Adaptin reported a net loss of $5.17 million and an accumulated deficit of $9.29 million. Cash and cash equivalents were $459,174, leading management to state substantial doubt about its ability to fund operations for the next twelve months without new capital. Operations are funded primarily through private placements and prior bridge notes that converted into equity.
The company holds an exclusive license from Duke University covering its BRiTE technology, owes clinical and commercial milestones totaling up to $11.7 million plus royalties, and relies on contract manufacturers and sponsored research at Duke. As of March 26, 2026, Adaptin had 8,786,229 common shares outstanding and an approximate non-affiliate equity market value of $9.3 million, with no active trading market for its stock.